

Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral Drugs and Biologics to Change Future Treatment Paradigm

<https://marketpublishers.com/r/PADBF9D32F3EN.html>

Date: February 2014

Pages: 55

Price: US\$ 2,500.00 (Single User License)

ID: PADBF9D32F3EN

Abstracts

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients' pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF- α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients. We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!

Contents

1. EXECUTIVE SUMMARY

2. UNMET NEED IN PSORIASIS

1. Limitations of Anti-TNFs
2. Scope for Entrants with Better Efficacy and Safety Profiles

3. SPECIFIC UNMET NEED AND EMERGING THERAPIES

1. Plaque Psoriasis
2. Psoriatic Arthritis

4. PIPELINE – BIOLOGICS PRODUCTS

1. IL-12 and IL-23 inhibitors
 1. Stelara
 2. tildrakizumab (MK-3222/ SCH 900222)
 3. Guselkumab (CNTO 1959)
 4. Fezakinumab (ILV-094)
2. Interleukin-17 (IL-17) and Receptor (IL-17RA)
 1. Secukinumab
 2. Ixekizumab (LY2439821)
 3. Brodalumab (AMG 827)
3. Other Targets
 1. Cimzia
 2. Itolizumab
 3. Tregalizumab

5. PIPELINE – ORAL TREATMENT

1. Targeting JAK-STATs
 1. Tofacitinib
 2. LY3009104
 3. INCB39110
 4. ASP015K
 5. GSK2586184
2. Phosphodiesterases 4 (PDE4) Inhibitor

1. OTEZLA
3. Other Targets
1. Sotrastaurin
2. LAS41008
3. Voclosporin
4. LLL 3348
5. CF101
6. Ponesimod
7. VB-201
8. FP187
9. GSK-2245840
10. IMO-8400

6. PIPELINE – TOPICAL TREATMENTS

1. M518101
2. CT327
3. DRM02
4. Xantryl
5. INCB18424
6. AN2728
7. MOL4249
8. DLX105

7. COMMERCIAL OUTLOOK

8. DISEASE OVERVIEW

1. Etiology and Pathophysiology of Psoriasis
2. Types of Psoriasis
3. Treatment Efficacy Tools

9. CURRENT TREATMENT OPTIONS

10. TREATMENT GUIDELINES FOR PSA

List Of Tables

LIST OF TABLES

- 1 Approved/ Marketed Products
- 2 A. Psoriasis' Pipeline: Small Molecules – Oral/ Injectable B. Psoriasis' Pipeline: Topical
- 3 Psoriasis' Pipeline: Biologics
- 4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis
- 5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis
- 6 Ixekizumab: Phase III Clinical Trial Designs
- 7 Brodalumab: Phase III Clinical Trial Designs
- 8 Clinical Data Comparison: Plaque Psoriasis – Biologics
- 9 A. Tofacitinib: PASI Improvement from Baseline B. Tofacitinib: Improvement in Quality-of-Life (QOL) Measures
- 10 Other Targets in Clinical Development for RA
- 11 Genes Associated with Psoriasis Susceptibility
- 12 Competitive Landscape: Plaque Psoriasis
- 13 Competitive Landscape: Psoriatic Arthritis
- 1 PFE's Xeljanz Launch vs. Other Recent RA Launches 3
- 2 The Structure and Function of the Cytokines IL-12 And IL-23
- 3 Clinical Data: ACCEPT – Head-To-Head Trial with Enbrel
- 4 MK-3222 Neutralizes IL-23, Specifically
- 5 Immunology and Immunotherapeutic Targets of Psoriasis
- 6 IL-17-Induced Signaling Pathways
- 7 Ixekizumab: Clinical Response (PASI And sPGA) @ week
- 8 Itolizumab Value Proposition with Marketed Products
- 9 Regulation of JAK–STAT Signaling
- 10 INCB39110: Response Rate - Exploratory Efficacy Analyses
- 11 ASP015K – Changes from Baseline in PASI at Day 42
- 12 PDE Inhibitors Crosstalk
- 13 AEB071 – PASI 75 Reductions Compared with Baseline
- 14 DRM02– Novel Mechanism of Action
- 15 DLX105 – Ph1a Results (PASI Changes @ Day 14)
- 16 Psoriasis Treatment Ladder (Schematic)
- 17 US Psoriasis Market Estimation
- 18 Proposed Schema of the Evolution of A Psoriatic Lesion
- 19 Distribution of Psoriasis Severity
- 20 Use of Therapies Depending on the Disease Severity

- 21 Targeted Therapy Classification Based on Pathogenesis
- 22 Comparison of GRAPPA and AAD Treatment Guidelines

List Of Figures

LIST OF FIGURES

- 1 PFE's Xeljanz Launch vs. Other Recent RA Launches
- 2 The Structure and Function of the Cytokines IL-12 And IL-23
- 3 Clinical Data: ACCEPT – Head-To-Head Trial with Enbrel
- 4 MK-3222 Neutralizes IL-23, Specifically
- 5 Immunology and Immunotherapeutic Targets of Psoriasis
- 6 IL-17-Induced Signaling Pathways
- 7 Ixekizumab: Clinical Response (PASI And sPGA) @ week 20
- 8 Itolizumab Value Proposition with Marketed Products
- 9 Regulation of JAK–STAT Signaling
- 10 INCB39110: Response Rate - Exploratory Efficacy Analyses
- 11 ASP015K – Changes from Baseline in PASI at Day 42
- 12 PDE Inhibitors Crosstalk
- 13 AEB071 – PASI 75 Reductions Compared with Baseline
- 14 DRM02– Novel Mechanism of Action
- 15 DLX105 – PhIa Results (PASI Changes @ Day 14)
- 16 Psoriasis Treatment Ladder (Schematic)
- 17 US Psoriasis Market Estimation
- 18 Proposed Schema of the Evolution of A Psoriatic Lesion
- 19 Distribution of Psoriasis Severity
- 20 Use of Therapies Depending on the Disease Severity
- 21 Targeted Therapy Classification Based on Pathogenesis
- 22 Comparison of GRAPPA and AAD Treatment Guidelines

I would like to order

Product name: Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral Drugs and Biologics to Change Future Treatment Paradigm

Product link: <https://marketpublishers.com/r/PADBF9D32F3EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PADBF9D32F3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

